debilitating condition of hyponatremia and its associated syndromes. In the present work, we present a novel and stereoselective synthesis that stems from the preparation of three key intermediates: the substituted benzenesulfonyl chloride 2, the N-protected oxindole 3, and protected dibromide 4. The synthesis of 1 has been achieved in good overall yield, each step proceeding in greater than 80% yield. In
SR 121463 A,1是一种有前途的非肽原型,可对血管
加压素V(2)受体亚型进行有效和选择性的拮抗作用,因此,它是控制低
钠血症及其相关综合征临床上令人衰弱的病症的候选人。在目前的工作中,我们提出了一种新颖的,立体选择性的合成方法,该方法源于三个关键中间体的制备:取代的
苯磺酰氯2,N保护的羟
吲哚3和保护的二
溴化物4。收率,每个步骤的收率均大于80%。另外,在立体
化学的完全控制下制备中间体2和1的顺式异构体。后者的减少似乎是通过
锂阳离子介导的螯合控制来进行的。